108 related articles for article (PubMed ID: 3742487)
1. In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycin.
Zylicz Z; Wagener DJ; van Rennes H; Wessels JM; van der Kleijn E; de Grip WJ; Ottenheijm HC; van den Broek LA
Cancer Lett; 1986 Jul; 32(1):53-9. PubMed ID: 3742487
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of cisplatin antitumor activity on L1210 leukemia s.c. by sparsomycin and three of its analogues.
Zylicz Z; Hofs HP; Wagener DJ
Cancer Lett; 1989 Jul; 46(2):153-7. PubMed ID: 2752385
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia.
Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; Van Zeist AJ; Van Den Broek LA; Ottenheijm HC
Anticancer Res; 1992; 12(1):167-70. PubMed ID: 1567164
[TBL] [Abstract][Full Text] [Related]
4. Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; van Zeist AJ; van den Broek LA; Ottenheijm HC
Cancer Chemother Pharmacol; 1993; 31(4):289-94. PubMed ID: 8422692
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agents.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; de Vos D; Doesburg WH; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1995 Apr; 6(2):277-84. PubMed ID: 7795276
[TBL] [Abstract][Full Text] [Related]
6. In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesis.
Zylicz Z; Wagener DJ; van Rennes H; Wessels JM; van der Kleijn E; de Grip WJ; van den Broek LA; Ottenheijm HC
J Natl Cancer Inst; 1987 Apr; 78(4):701-5. PubMed ID: 3470545
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo.
Catino JJ; Francher DM; Schurig JE
Cancer Chemother Pharmacol; 1986; 18(1):1-4. PubMed ID: 3757151
[TBL] [Abstract][Full Text] [Related]
8. The effect of ethyldeshydroxy-sparsomycin and cisplatin on the intracellular glutathione level and glutathione S-transferase activity.
Hofs HP; Wagener TD; de Valk-Bakker V; van Rennes H; Doesburg WH; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1997 Apr; 8(4):349-57. PubMed ID: 9180388
[TBL] [Abstract][Full Text] [Related]
9. Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.
Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; De Vos D; Doesburg WH; Ottenheijm HC; De Grip WJ
Invest New Drugs; 1995; 13(1):23-32. PubMed ID: 7499104
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models.
Zylicz Z; Wagener DJ; van Rennes H; van der Kleijn E; Lelieveld P; van den Broek LA; Ottenheijm HC
Invest New Drugs; 1988 Dec; 6(4):285-92. PubMed ID: 3229941
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice.
Novotny L; Rauko P; Liska J; Elford HL; Szekeres T
Cancer Lett; 2006 Feb; 233(1):178-84. PubMed ID: 15885888
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of sparsomycin analogs as potential antitumor agents.
Dubois RJ; Lin CC; Michel BL
J Pharm Sci; 1975 May; 64(5):825-9. PubMed ID: 1151655
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine.
Rauko P; Novotny L; Dovinova I; Hunakova L; Szekeres T; Jayaram HN
Eur J Pharm Sci; 2001 Feb; 12(4):387-94. PubMed ID: 11231105
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and toxicology of sparsomycin in beagle dogs.
Zylicz Z; Wagener DJ; Fernandez del Moral P; van Rennes H; Wessels JM; Winograd B; van der Kleijn E; Vree TB; van Haelst U; van den Broek LA
Cancer Chemother Pharmacol; 1987; 20(2):115-24. PubMed ID: 3664930
[TBL] [Abstract][Full Text] [Related]
16. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I
Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494
[TBL] [Abstract][Full Text] [Related]
17. Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study.
van den Broek LA; Lázaro E; Zylicz Z; Fennis PJ; Missler FA; Lelieveld P; Garzotto M; Wagener DJ; Ballesta JP; Ottenheijm HC
J Med Chem; 1989 Aug; 32(8):2002-15. PubMed ID: 2754719
[TBL] [Abstract][Full Text] [Related]
18. Synergism of the polyamine analogue, N1,N11-bisethylnorspermine with cis-diaminedichloroplatinum (II) against murine neoplastic cell lines in vitro and in vivo.
Hawthorne TR; Austin JK
Cancer Lett; 1996 Jan; 99(1):99-107. PubMed ID: 8564936
[TBL] [Abstract][Full Text] [Related]
19. Effect of thymidine on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II).
Grossie VB; Valdivieso M; Drewinko B; Loo TL
Cancer Chemother Pharmacol; 1984; 13(1):27-30. PubMed ID: 6539657
[TBL] [Abstract][Full Text] [Related]
20. [Ecdysterone modulates antitumor activity of cytostatics and biosynthesis of macromolecules in tumor-bearing animals].
Konovalova NP; Mitrokhin IuI; Volkova LM; Sidorenko LI; Todorov IN
Izv Akad Nauk Ser Biol; 2002; (6):650-8. PubMed ID: 12561325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
